



REPORT OF FACTUAL FINDINGS IN CONNECTION WITH ANNUAL PROGRESS REPORT OF CITI PHARMA LIMITED

Purpose

We have performed the procedures agreed with you and enumerating below with respect to preeledrined inspection items. Our engagement was in accordance with international standard on rollandservices (ISRS 4400) to perfume agreed upon procedures regarding financial information. The procedures were solely to assist Citi pharma limited (the company) to demonstrate to the investors, upon request about the progress of the expansion.

This report relates to annual progress report which is being submitted in compliance with the requirements of clause 16 (000) of post issue reporting and disclosures of the "Public offering regulations, 2017" and in pursuance of the requirement specified in clause 4 (ii) (2) (b) (2) of the prospectus to the issue of the company and may not be suitable for any other purpose.

Responsibility of Citi pharma Limited

Citi pharma limited has acknowledged that the agreed-upon procedures are appropriate for the purpose of the engagement.

Citi pharma limited (also the responsible party) is responsible for the subject matter on which the agreed upon procedures are performed.

Auditors' responsibility

We have conducted the agreed up-on procedures engagement in accordance with international standard on relating services (ISRS) 4400 (Revised), agreed upon procedures involves our procedures that have been agreed with Citi pharma limited, and reporting the findings which are the factual results of secred up-on procedures performed.

This agreed up-on procedures engagement is not an assurance engagement. Accordingly, we do not express an opinion or an assurance conclusion Had we performed additional procedures, other matters might have come to our attention that would have been reported.

Professional ethics and quality control

We have compiled with the independence and other ethical requirements of the code of ethics for chartered accountants issued by the institute of chartered accountants of Pakistan, which is founded on fundamental principles of integrity, objectivity, professional competence and dur care, confidentiality and professional behavior.

The firm applies international standards on quality control 1 "quality control for firms that perform Audits and reviews of historical financial information, and other assurance and related services engagements" and accordingly maintain a comprehensive system of quality control including

documented policies and procedures regarding compliance with the ethical requirements, professional standards and applicable legal and regulatory requirements

Procedures and findings

We have performed the procedure described below, which were agreed with (the Company) in terms of its IPO progress report.

| S.no | Procedures performed | Findings |
|------|---|---|
| 1 | Ensured that all the required information as per "Public Offering Regulations,2017" is appropriately disclosed in Annual Progress Report for the period July 01, 2023 to December 31, 2023. | With respect to item 1 all the required information as per "Public Offering Regulations, 2017" is appropriately disclosed |
| 2 | Reviewed following document: Books & Accounts of the company for the period July 01, 2023 to December 31, 2023. Prospectus for issue of shares dated February 12, 2021. | With respect to item 2 we found the amounts compared to be in agreement |
| 3 | Inspected the minutes of meeting of Board of Directors (BOD) to check any progress has been made relating to API Segment, Formulation Segment and Hospital Facility during the period July 01, 2023 to December 31, 2023. | With respect to item 3 we found the addition amounting to Rupees, 71.80 million and Rupees 26.91 million in API Segment and Formulation Segment respectively, to be correct and the total amount to be in agreement. However, no amount has been invested on Hospital Facility as of the period end |
| 4 | Inspect the minutes of board of directors meeting for the approval of the capital expenditure for the period ended December 31, 2023. | With respect to item 4 We found that BOD approved the capital expenditure |
| 5 | Matched the amount shown as funds required under the heading of 'implementation status' on page 4 of the progress report with the prospectus. | With respect to item 5 we found the amounts compared to be in agreement |
| 6 | Matched actual expenditure incurred till December 31, 2023 under the heading 'implementation status' on page 4 of the progress report with books and accounts of the company. | With respect to item 6 we found the actual expenditure incurred till December 31, 2023 under the heading "implementation status, compared to be in agreement |

Yours sincerely

Summarich D

Aslam Malik & Co.
Chartered Accountants
Date: February 13, 2024

UTILIZATION OF IPO PROCEEDS HALF YEARLY PROGRESS REPORT DECEMBER 31, 2023

| | ole of Contents | 2 |
|----|----------------------------------|---|
| SU | IMMARY OF FUNDS GENERATED | 2 |
| IM | IPLEMENTATION STATUS | 3 |
| 1. | SUMMARY OF IPO FUNDS UTILIZED | 3 |
| 2. | Expansion in API Segment | 4 |
| 3. | Expansion In Formulation Segment | 5 |
| 4. | Establishment of Hospital | 6 |
| 5. | INVESTMENT IN WORKING CAPITAL | 7 |

INTRODUCTION

This semi-annual progress report is being submitted in compliance with the requirement of Clause 16(1)(ii) of post-issue reporting and disclosures of the Public Offering Regulations, 2017 and in pursuance of the requirement specified in clause 4(ii)(2)(b)(2) of the prospectus to the issue of the Company.

The Company carried out a successful IPO in July 2021, to finance its expansions, at estimated costs, as detailed below:

| Description | Funds Required (Rupees) | Allocation (%) |
|--|-------------------------------|-------------------|
| API Segment | | |
| Civil Works | 150,000,000 | 7% |
| Procurement of Plant and Machinery | 405,194,500 | 20% |
| | 555,194,500 | 27.28% |
| Formulation Segment | | |
| Civil Works | 250,000,000 | 12% |
| Procurement of Plant and Machinery | 307,630,000 | 15% |
| | 557,630,000 | 27.40% |
| Hospital Facility | | |
| Civil Work of Hospital Building (incl. Electrical and Mechanical work) | 668,000,000 | 33% |
| Plant and Machinery for Hospital | 254,551,500 | 13% |
| | 922,551,500 | 45.33% |

SUMMARY OF FUNDS GENERATED

| Description | Rupees |
|--|---------------|
| Issuance of 72,692,000 shares at a floor price of Rs. 28 per share | 2,035,376,000 |
| Excess funds received Share Premium at Rs. 4 per share | 290,768,000 |
| Less: IPO Expenses | (127,667,864) |
| Net IPO Proceeds | 2,198,476,136 |
| Less: Funds utilized for repayment of borrowings and for working capital | (163,100,136) |
| Net Funds Available | 2,035,376,000 |

IMPLEMENTATION STATUS

1. SUMMARY OF IPO FUNDS UTILIZED

The status of the expansion project as of the close of December 31, 2023 is given below on prescribed format:

| Description | Funds Required (Rupees) | Allocati on (%) | Actual Expenditure (Rupees) | Excess/ (Less) Incurred (Rupees) |
|--|----------------------------|--------------------|---|--|
| API Segment | | | N 15 - 3 15 15 15 15 15 15 15 15 15 15 15 15 15 | |
| Civil Works | 150,000,000 | 7% | 150,000,000 | |
| Procurement of Plant and Machinery | 405,194,500 | 20% | 291,741,077 | (113,453,423) |
| | 555,194,500 | 27.28% | 441,741,077 | (113,453,423) |
| Formulation Segment | | | | |
| Civil Works | 250,000,000 | 12% | 154,219,142 | (95,780,858) |
| Procurement of Plant and Machinery | 307,630,000 | 15% | 219,954,802 | (87,675,198) |
| | 557,630,000 | 27.40% | 374,173,944 | (183,456,056) |
| Hospital Facility | | | | |
| Civil Work of Hospital Building (Incl. Electrical and Mechanical work) | 668,000,000 | 33% | | (668,000,000) |
| Plant and Machinery for Hospital | 254,551,500 | 13% | | (254,551,500) |
| | 922,551,500 | 45.33% | | (922,551,500) |
| Utilization of Excess Proceeds | | | | |
| Repayment of Borrowings | 54,197,497 | 19% | 54,197,497 | |
| Working Capital | 108,902,639 | 37% | 108,902,639 | |
| IPO Expenses | 127,667,864 | 44% | 127,667,864 | |
| | 290,768,000 | 100% | 290,768,000 | |

2. Expansion in API Segment

As of June 30, 2024, Cell work for the expansion of paracetamol and a new multi-purpose AP facility for new APR, Ascorbic acid, Chloroquine Phosphate and Hydrory, Chloroquine Phosphate was completed. In Plant and Machinery, eight Reactors 101, three Reactors 7.01, three Reactors 7

Implementation Status

| Particulars | Start Date (As per Prospectus) | Completion Date (As per Prospectus) | Current Status | Rationale for Delay if any |
|-----------------------------------|--------------------------------------|--|-------------------|---|
| Civil Work of API Segment | 3QFY21 | 2QFY22 | 100% Completed | Completed in 2QFY23 |
| Plant & machinery for API Segment | 3QF/21 | 3QFY22 | 72% Completed | Will be completed in this Financia Year. |
| Trial Production of New APIs | 1QFY22 | 3QFY22 | 33% | Expected to be completed before the financial year 2024. |

3. Expansion in Formulation Segment

As of December 31, 2023, Civil work for Cephalosporin has been completed. Civil work has been completed by our in-house engineering team. Construction work for Psychotropic & Narrotics and Penicillin is in progress and expected to be completed before the end of the financial year 2024.

Further following list of Plant and Machinery has been procured which was committed prospectus:

- Clean Rooms for Machinery Vial Filling, Stoppering Machine, Vial Capping Machine
 - > High performance Liquid Chromatography HPLC
 - Vial Capping Machine
 - > HPLC
- > Automated Capsule Filling Machine
 - Rotary Tablet Press Machine ZP41A
 Automated Blister Packing Machine
 - > Tropical Blister Packing Machine
 - Rotary Tablet Press Machine ZP29D
 Lab Equipment

Implementation Status

| Particulars | Start Date (As per Prospectus) | Completion Date (As per Prospectus) | Current Status | Rationale for Delay if any |
|--|--------------------------------------|-------------------------------------|----------------|---|
| Civil Work of Formulation Segment | 3QFY21 | 2QFY22 | 62% Completed | Will be completed in this Financial Year. |
| Plant & Machinery of Formulation Segment | 1QFY22 | 1QFY23 | 72% Completed | Will be completed in this Financial Year. |
| Trial Production of New Formulation Drugs | 3QFY22 | 4QFY22 | 33% Completed | Will be completed in this Financial Year. |

4 Establishment of Hospital

The project delay of the hospital primarily stems from the complexities and challenges associated with various procedural activities. These activities encompass a range of administrative, regulatory and bureaucratic processes that are essential for the successful planning, approval and execution of a hospital project.

Implementation Status

| Particulars | (As per Prospectus) | Completion Date (Ac per Prospectus) | Rationale for Delay if any | |
|--------------------------------------|------------------------|--|-------------------------------|------|
| Completion of Civil Work | 1QFY22 | 1QFY23 | Not Started | N/A* |
| Procurement of Medical Equipment | 3QFY22 | 1QFY23 | Not Started | N/A* |
| Procurement of Fixtures and Fittings | 4QFY22 | 1QFY23 | Not Started | N/A* |

*The original prospectise outlined the establishment of the hospital at Guldberg, Lahore, where the company had capited 4 stands of land, knowers, the to registary constraints imposed by the lahore Development Authority (LIA), which further reduced the permissible contraction save the lahore the reduced the permissible contraction have a state of the contraction of the lahore the reduced the permissible contraction that adjacent to contract the company was completed to reconside this bostom. The Guldberg glot is staated adjacent to cadedit 55dam on one side and an insum Bargain on the other, creating an environment with anticipated node levies and pages constraints that would significantly entire the hospital's operational efficiency and patient can following an internal survey and broowing between the contractions of the contraction of

The company has acquired land for hospital at the proposed site at DHA Rahbar, Rahwid Raku, Lahone, provides a more suitable environment for the hospital, ensuring full compliance with IDA. Ore regulations. Additionally, the company was in the process of completing the commercialization of the DHA Rahbar land, which took additional time. This relocation aligns with the company's commitment to establishing a facility that meets the highest standards of operational efficiency and patient care.

5. INVESTMENT IN WORKING CAPITAL

The Company had evaluated its working capital requirement based on previous trends, requirements and future business outlook and the expected amount was allocated in the prospectus.

As at December 31, 2023, the funds allocated for the working capital have been fully utilized, and have been rolled over multiple times in the working capital cycle.

Ghulam Dastgeer Company Secretary Asif Iqbal